中廣核技(000881.SZ)簽署投資協議書 擬2.7億元建設醫用同位素生產基地項目
格隆匯11月26日丨中廣核技(000881.SZ)公佈,為進一步落實A+發展戰略,發展核藥業務,公司與遊仙區人民政府簽署了《(綿陽)醫用同位素生產基地項目投資協議書》,擬在綿陽市遊仙區中國(綿陽)科技城核醫療健康產業園建設醫用同位素生產基地項目,項目投資總額2.7億元人民幣。
該項目為公司首個醫用放射性同位素生產及銷售項目,採用30-35MeV中能迴旋加速器生產醫用放射性同位素鍺[68Ge]、碘[123I],並基於鍺[68Ge]生產醫用鍺鎵發生器。根據市場需要,可增加生產其他醫用同位素如銦[111In]、鋯[89Zr]、鈧[44Sc]、鈧[43Sc]、鈧[47Sc]等。公司還將與國內外其他醫用同位素生產商合作,代理銷售相關產品,以“堆器集合、診療一體”為目標,逐步打造完整的醫用放射性同位素產業鏈。
當前,在全球範圍內面臨着同位素供應短缺的局面,長期以來嚴重製約了核醫學與核藥的發展;除氟[18F]、碘[131I]外,國內幾乎沒有商業化的同位素生產。本次項目落地,有利於抓住市場機遇,快速進入醫用同位素生產領域,實現核醫學顯像診斷領域多產品的佈局,有利於進一步開展醫用同位素生產與應用的研究,為核藥發展打好基礎,符合公司“A+戰略”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.